<DOC>
	<DOCNO>NCT00114257</DOCNO>
	<brief_summary>This phase I trial study side effect best dose decitabine FR901228 treat patient relapsed refractory leukemia , myelodysplastic syndrome myeloproliferative disorder . Drugs use chemotherapy , decitabine FR901228 , work different way stop growth cancer cell , either kill cell stop dividing . FR901228 may also stop growth cancer cell block enzymes need cell growth block blood flow cancer . Giving decitabine together FR901228 may kill cancer cell .</brief_summary>
	<brief_title>Decitabine FR901228 Treating Patients With Relapsed Refractory Leukemia , Myelodysplastic Syndromes , Myeloproliferative Disorders</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose decitabine FR901228 ( depsipeptide ) patient relapse refractory leukemia , myelodysplastic syndrome , myeloproliferative disease . II . Determine safety tolerability regimen patient . SECONDARY OBJECTIVES : I . Determine clinical activity regimen patient . OUTLINE : This dose-escalation study . Patients receive decitabine IV 1 hour day 1-5 8-12 FR901228 ( depsipeptide ) IV 4 hour day 5 12 OR day 5 , 12 , 19 . Treatment repeat every 4-6 week least 2 course absence disease progression unacceptable toxicity . Patients experience complete remission 1 year remove study . Cohorts 6 patient receive escalate dos decitabine FR901228 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 follow hematologic malignancy : Acute myeloid leukemia Previously untreated patient &gt; 60 year age eligible frontline therapy eligible study Acute lymphoblastic leukemia Chronic myelogenous leukemia ( CML ) Documented hematologic resistance imatinib mesylate OR cytogenetic response 12 month prior treatment imatinib mesylate Philadelphia chromosomenegative CML allow provided disease resistant standard therapy ( e.g. , hydroxyurea ) OR disease progress ( blast &gt; 5 % platelet count &lt; 100,000/mm^3 ) standard therapy Myelodysplastic syndromes International Prognostic Scoring System risk category ≥ intermediate1 Patients eligible frontline therapy eligible study Myeloproliferative disease Chronic lymphocytic leukemia Failed progressed ≥ 1 prior fludarabinebased therapy AND alemtuzmab Acute promyelocytic leukemia Progressed prior treatment standard chemotherapy , tretinoin , arsenic trioxide Chronic myelomonocytic leukemia Resistant standard therapy ( e.g. , hydroxyurea ) OR disease progress ( blast &gt; 5 % platelet count &lt; 100,000/mm^3 ) standard therapy Relapsed refractory disease No known brain meningeal disease PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 01 Life expectancy More 8 week Hepatic Bilirubin &lt; 2 mg/dL AST ALT ≤ 2.5 time upper limit normal Renal Creatinine &lt; 2 mg/dL Cardiovascular QTc &lt; 500 msec LVEF &gt; 40 % MUGA No New York Heart Association class III IV congestive heart failure No myocardial infarction within past year No uncontrolled dysrhythmias No uncontrolled angina No leave ventricular hypertrophy EKG No history serious ventricular arrhythmia ( e.g. , ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No significant cardiac disease Immunologic No history allergic reaction attribute compound similar chemical biologic composition study drug No ongoing active infection No HIV positivity Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : Chemotherapy Recovered prior chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) unless evidence rapidly progressive disease Radiotherapy At least 4 week since prior radiotherapy recover Other No concurrent agent cause QTc prolongation No concurrent investigational commercial agent therapy malignancy No concurrent hydrochlorothiazide Concurrent potassiumconserving combination ( e.g. , Maxide® Dyazide® ) antihypertensive agent allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
</DOC>